Literature DB >> 11126514

Immunological properties of Hn-33 purified from type A Clostridium botulinum.

S K Sharma1, B R Singh.   

Abstract

Type A botulinum neurotoxin is produced along with 6-7 neurotoxin associated proteins to form a complex in addition to the neurotoxin. Immunological reactivity of type A botulinum complex and purified hemagglutinin (Fu et al., 1998) to polyclonal antibody raised against the complex have been investigated using ELISA. In competitive ELISA, 50% inhibition of the binding of IgG antibody against complex A is observed at 78 ng/ml of complex and hemagglutinin-33, suggesting that the hemagglutinin-33 accounts for most of the immunogenic response of the complex. Considering the fact that the complex consists of a group of proteins with a cumulative molecular weight of 900 kDa, hemagglutinin-33 may be one of the major immunoreactive proteins present in the type A neurotoxin complex.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126514

Source DB:  PubMed          Journal:  J Nat Toxins        ISSN: 1058-8108


  13 in total

1.  Detection and confirmation of Clostridium botulinum in water used for cooling at a plant producing low-acid canned foods.

Authors:  Amita Sachdeva; Stephanie L H Defibaugh-Chávez; James B Day; Donald Zink; Shashi K Sharma
Journal:  Appl Environ Microbiol       Date:  2010-10-01       Impact factor: 4.792

2.  Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.

Authors:  Anne-Marie Bryant; Shuowei Cai; Bal Ram Singh
Journal:  Toxicon       Date:  2013-06-28       Impact factor: 3.033

3.  Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex.

Authors:  Ellen R Goldman; George P Anderson; Jerry Conway; Laura J Sherwood; Melissa Fech; BaoHan Vo; Jinny L Liu; Andrew Hayhurst
Journal:  Anal Chem       Date:  2008-10-24       Impact factor: 6.986

4.  Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies.

Authors:  Shashi K Sharma; Joseph L Ferreira; Brian S Eblen; Richard C Whiting
Journal:  Appl Environ Microbiol       Date:  2006-02       Impact factor: 4.792

5.  Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Authors:  Jürgen Frevert; Dirk Dressler
Journal:  Biologics       Date:  2010-12-09

6.  A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.

Authors:  Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2011-12-23       Impact factor: 2.570

7.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

Review 8.  A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses.

Authors:  James P Bonaparte; David Ellis; Jason G Quinn; Mohammed T Ansari; Jessica Rabski; Shaun J Kilty
Journal:  Syst Rev       Date:  2013-06-13

9.  Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait.

Authors:  Maurizio Falso; Rosalba Galluso; Andrea Malvicini
Journal:  Neurol Int       Date:  2012-05-29

10.  Neurotoxin Impurities: A Review of Threats to Efficacy.

Authors:  Je-Young Park; Owen Sunga; Rungsima Wanitphakdeedecha; Jürgen Frevert
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.